Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acupuncture vs no treatment Presence or absence of urinary urgency · overactive bladder in adults Acupuncture for treating overactive bladder in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs no treatment Episodes of urinary incontinence in a 24‐hour period · overactive bladder in adults Acupuncture for treating overactive bladder in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs no treatment Daytime urinary frequency · overactive bladder in adults Acupuncture for treating overactive bladder in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs no treatment Episodes of nocturia · overactive bladder in adults Acupuncture for treating overactive bladder in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Any intervention vs steroid alone or plus levofloxacin Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical steroid vs artificial tears Proportion of participants with resolution of signs within 7 days of treatment (higher is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical steroid vs artificial tears Proportion of participants in whose eyes SEI had disappeared within 21 days of treatment initiation (higher is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical steroid vs artificial tears Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical steroid vs artificial tears Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Any intervention vs artificial tears or saline Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Any intervention vs artificial tears or saline Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Statins with cholesterol supplementation vs cholesterol supplementation only Overall survival · children and adults with Smith‐Lemli‐Opitz syndrome Statins for Smith‐Lemli‐Opitz syndrome (2022) · Cochrane | no estimate extracted | NR | No studies |
Statins with cholesterol supplementation vs cholesterol supplementation only QoL · children and adults with Smith‐Lemli‐Opitz syndrome Statins for Smith‐Lemli‐Opitz syndrome (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pregabalin 300 mg vs placebo Complete abortion rate ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pregabalin 300 mg vs placebo Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pregabalin 300 mg vs placebo Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Gastrointestinal side effects (nausea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Gastrointestinal side effects (nausea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Gastroinestinal side effects (vomiting) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Gastrointestinal side effects (vomiting) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Therapeutic ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Therapeutic ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Therapeutic ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
PCC vs FVIIa Adverse events · cardiac surgery for the treatment of non‐surgical bleeding Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding (2022) · Cochrane | no estimate extracted | NR | No studies |
PCC vs standard treatment Adverse events · cardiac surgery for the treatment of non‐surgical bleeding Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution Death · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution Development of antibiotic resistance · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution Adverse effects · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Catheter guidewire exchange vs catheter removal and replacement Stenosis or thrombosis of vascular access site after catheter removal · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Catheter guidewire exchange vs catheter removal and replacement Death · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Catheter guidewire exchange vs catheter removal and replacement Development of antibiotic resistance · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Catheter guidewire exchange vs catheter removal and replacement Adverse effects · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin Stenosis or thrombosis of vascular access site after catheter removal · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin Death · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin Development of antibiotic resistance · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin Adverse effects · patients on maintenance HD with CRBSI Interventions for treating catheter‐related bloodstream infections in people receiving maintenance… (2022) · Cochrane | no estimate extracted | NR | No studies |